Pharmacological inhibitors of NAD(P)H quinone oxidoreductase, NQO1: Structure/activity relationships and functional activity in tumour cells

Biochemical Pharmacology

Volumn 80, Issue 7, 2010, Pages 977-981

  Nolan, Karen Ann ^a   Scott, Katherine Ann ^a   Barnes, John ^a   Doncaster, Jeremy ^a   Whitehead, Roger Clive ^a   Stratford, Ian James ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Coumarins; Dicoumarol; EO9; NQO1; P53

Indexed keywords

APAZIQUONE; COUMARIN DERIVATIVE; DICOUMAROL; NADPH QUINONE OXIDOREDUCTASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AZIRIDINE DERIVATIVE; INDOLE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NQO1 PROTEIN, HUMAN; PROTEIN; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ARTICLE; CELL ACTIVITY; CELL FREE SYSTEM; CELL FUNCTION; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TUMOR CELL; ANTAGONISTS AND INHIBITORS; METABOLISM; NEOPLASM;

ANTINEOPLASTIC AGENTS; AZIRIDINES; DICUMAROL; HUMANS; INDOLEQUINONES; NAD; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASMS; PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77955653661     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.06.024     Document Type: Article

References (36)

1. Li R., Bianchet M.A., Talalay P., Amzel L.M. The three-dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: mechanism of the two-electron reduction. Proc Natl Acad Sci U S A 1995, 92:8846-8850.
2. Siegel D., Gustafson D.L., Dehn D.L., Han J.Y., Boonchoong P., Berliner L.J., et al. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol 2004, 65:1238-1247.
3. Asher G., Lotem J., Cohen B., Sachs L., Shaul Y. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci U S A 2001, 98:1188-1193.
4. Asher G., Bercovich Z., Tsvetkov P., Shaul Y., Kahana C. 20S proteasomal degradation of ornithine decarboxylase is regulated by NQO1. Mol Cell 2005, 17:645-655.
5. Tsvetkov P., Asher G., Reiss V., Shaul Y., Sachs L., Lotem J. Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. Proc Natl Acad Sci U S A 2005, 102:5535-5540.
6. Gong X., Kole L., Iskander K., Jaiswal A.K. NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53. Cancer Res 2007, 67:5380-5388.
7. Asher G., Lotem J., Tsvetkov P., Reiss V., Sachs L., Shaul Y. P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1. Proc Natl Acad Sci U S A 2003, 100:15065-15070.
8. Garten S., Wosilait W.D. Comparative study of the binding of coumarin anticoagulants and serum albumins. Biochem Pharmacol 1971, 20:1661-1668.
9. Du J., Daniels D.H., Asbury C., Venkataraman S., Liu J., Spitz D.R., et al. Mitochondrial production of reactive oxygen species mediate dicumarol-induced cytotoxicity in cancer cells. J Biol Chem 2006, 281:37416-37426.
10. Collier A.C., Pritsos C.A. The mitochondrial uncoupler dicumarol disrupts the MTT assay. Biochem Pharmacol 2003, 66:281-287.
11. Nolan K.A., Zhao H., Faulder P.F., Frenkel A.D., Timson D.J., Siegel D., et al. Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1 Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity. J Med Chem 2007, 50:6316-6325.
12. Nolan K.A., Doncaster J.R., Dunstan M.S., Scott K.A., Frenkel A.D., Siegel D., et al. Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem 2009, 52:7142-7156.
13. Workman P. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol Res 1994, 6:461-475.
14. Robertson N., Stratford I.J., Houlbrook S., Carmichael J., Adams G.E. The sensitivity of human tumour cells to quinine bioreductive drugs: what role for DT-diaphorase?. Biochem Pharmacol 1992, 44:409-412.
15. Walton M.I., Bibby M.C., Double J.A., Plumb J.A., Workman P. DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas. Eur J Cancer 1992, 28A:1597-1600.
16. Fitzsimmons S.A., Workman P., Grever M., Paull K., Camalier R., Lewis A.D. Reductase enzyme expression across the National Cancer Institute Tumor cells line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 1996, 88:259-269.
17. Maliepaard M., Wolfs A., Groot S.E., de Mol N.J., Janssen L.H. Indoloquinone EO9:DNA interested cross-linking upon reduction by DT-diaphorase or xanthine oxidase. Br J Cancer 1995, 71:836-839.
18. Bailey S.M., Wyatt M.D., Friedlos F., Hartley J.A., Knox R.J., Lewis A.D., et al. Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9. Br J Cancer 1997, 76:1596-1603.
19. Robertson N., Haigh A., Adams G.E., Stratford I.J. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur J Cancer 1994, 30A:1013-1019.
20. Plumb J.A., Gerritsen M., Workman P. DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. Br J Cancer 1994, 70:1136-1143.
21. Jaffar M., Naylor M.A., Robertson N., Lockyer S.D., Phillips R.M., Everett S.A., et al. 5-Substituted analogues of 3-hydroxymethyl-5-aziridinyl-1-methyl-2-[1H-indole-4,7-dione]prop-2-en-1-ol (EO9, NSC 382459) and their regioisomers as hypoxia-selective agents: structure-cytotoxicity in vitro. Anticancer Drug Des 1998, 13:105-123.
22. Phillips R.M. Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4, 7-dione]prop-beta-enalpha-ol (EO9) by human DT-diaphorase. Biochem Pharmacol 1996, 52:1711-1718.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Met 1983, 65:55-63.
24. Hulse M., Feldman S., Bruckner J.V. Effect of blood sampling schedules on protein drug binding in the rat. J Pharmacol Exp Ther 1981, 218:416-420.
25. Ross D., Siegel D., Beall H., Prakash A.S., Mulcahy R.T., Gibson N.W. DT-diaphorase in activation and detoxification of quinones bioreductive activation of mitomycin C. Cancer Metastasis Rev 1993, 12:83-101.
26. Phillips R.M. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase EC 1. 6. 99. 2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development. Biochem Pharmacol 1999, 58:303-310.
27. Winski S.L., Faig M., Bianchet M.A., Siegel D., Swann E., Fung K., et al. Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches. Biochemistry 2001, 40:15135-15142.
28. Dehn D.L., Siegel D., Swann E., Moody C.J., Ross D. Biochemical, cytotoxic, and genotoxic effects of ES936, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, in cellular systems. Mol Pharmacol 2003, 64:714-720.
29. Yan C., Shieh B., Reigan P., Zhang Z., Colucci M.A., Chilloux A., et al. Potent activity of indolequinones against human pancreatic cancer: identification of thioredoxin reductase as a potential target. Mol Pharmacol 2009, 76:163-172.
30. González-Aragón D., Alcaín F.J., Ariza J., Jódar L., Barbarroja N., López-Pedrera C., et al. ES936 stimulates DNA synthesis in HeLa cells independently on NAD(P)H:quinone oxidoreductase 1 inhibition, through a mechanism involving p38 MAPK. Chem Biol Interact 2010, Apr 28. [Epub ahead of print].
31. Long D.J., Waikel R.L., Wang X.J., Perlaky L., Roop D.R., Jaiswal A.K., et al. NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. Cancer Res 2000, 60:5913-5915.
32. Iskander K., Gaikwad A., Paquet M., Long D.J., Brayton C., Barrios R., et al. Lower induction of p53 and decreased apoptosis in NQO1-null mice lead to increased sensitivity to chemical-induced skin carcinogenesis. Cancer Res 2005, 65:2054-2058.
33. Iskander K., Barrios R.J., Jaiswal A.K. Disruption of NAD(P)H:quinone oxidoreductase 1 gene in mice leads to radiation-induced myeloproliferative disease. Cancer Res 2008, 68:7915-7922.
34. Ahn K.S., Sethi G., Jain A.K., Jaiswal A.K., Aggarwal B.B. Genetic deletion of NAD(P)H:quinone oxidoreductase 1 abrogates activation of nuclear factor-kappaB, IkappaBalpha kinase, c-Jun N-terminal kinase, Akt, p38, and p44/42 mitogen-activated protein kinases and potentiates apoptosis. J Biol Chem 2006, 281:19798-19808.
35. Strom E., Sathe S., Komarov P.G., Chernova O.B., Pavlovska I., Shyshynova I., et al. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2006, 2:474-479.
36. Ghosh S.P., Perkins M.W., Hieber K., Kulkarni S., Kao T.C., Reddy E.P., et al. Radiation protection by a new chemical entity, Ex-Rad: efficacy and mechanisms. Radiat Res 2009, 171:173-179.